Effectiveness and safety of dapsone 5% versus clindamycin 1% in the treatment of mild to moderate pimples

Phase 4

Completed

• Conditions: Health Condition 1: null- All the patients, aged 12 to 42 years of either sex, presenting with mild to moderate acne(â?¥ 2 but â?¤ 30 total lesions ).

• Registration Number: CTRI/2017/08/009582
• Lead Sponsor: Medical College Kolkata

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-01-27
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 51

Inclusion Criteria

1.Subjects of 12 to 40 years of age of either sex

2.Mild to moderate acne: >= 2 but <= 30 total lesions - inflammatory (papules and pustules) and/or non-inflammatory (open and closed comedones)

3.Lesions in the face which correspond to a baseline investigator global assessment (IGA) score of 2 or 3

Exclusion Criteria

1.Age <12 or >40

2.Total lesion count < 2 or >30,

3.Subjects regularly using any anti-acne medications in the last 30 days before study entry

4.Severe acne: Subjects with nodulo-cystic lesions, acne conglobata, acne fulminans

5.Pregnancy or intention of pregnancy and breastfeeding

6.Patients with G6PD deficiency

7.History of having taken any medication that could interact with dapsone (e.g. Trimetoprim-sulfametoxazol

8.Known hypersensitivity to the study medication

9.Patients not willing to comply with protocol requirements

Study & Design

• Study Type: Interventional
• Study Design: Not specified